0001830214FALSE00018302142023-11-082023-11-080001830214us-gaap:CommonClassAMember2023-11-082023-11-080001830214us-gaap:WarrantMember2023-11-082023-11-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________
FORM 8-K
______________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 8, 2023
______________________________________________________________
GINKGO BIOWORKS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
______________________________________________________________
Delaware001-4009787-2652913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
27 Drydock Avenue
8th Floor
Boston, MA 02210
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (877) 422-5362
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Class A common stock, par value $0.0001 per shareDNANYSE
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per shareDNA.WSNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02. Results of Operations and Financial Condition.
On November 8, 2023, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
Exhibit
Number
Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GINKGO BIOWORKS HOLDINGS, INC.
Date: November 8, 2023By:/s/ Mark Dmytruk
Name:Mark Dmytruk
Title:Chief Financial Officer


Exhibit 99.1
logoa.jpg
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023
Entered into strategic cloud and AI partnership with Google Cloud; first milestone recently achieved
Signed new multi-target RNA drug discovery collaboration with Pfizer in which Ginkgo is eligible to receive research fees and development and commercial milestone payments of up to $331 million
Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as Ginkgo continues to drive towards profitability
BOSTON, Mass – November 8, 2023 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2023. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

“We have continued to expand our customer base and partnerships this quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re particularly excited about our new program with Pfizer to advance the discovery and development of novel RNA molecules. I’m also thrilled about the five-year strategic cloud and AI partnership we signed with Google Cloud to deploy and develop AI tools for biology and biosecurity. Our team is hard at work building new, state-of-the-art foundation models that speak the languages of biology, and I couldn’t be more excited about the opportunities that lie ahead.”

Recent Business Highlights & Strategic Positioning
Added 21 new Cell Programs to the Foundry platform in Q3 2023, representing 40% growth over the prior year period
Includes a multi-target RNA drug discovery collaboration with Pfizer, in which Ginkgo is eligible to receive fees and milestones up to $331 million in addition to potential royalties on sales
Entered a strategic five-year cloud and AI partnership with Google Cloud to pioneer new large language models for biological engineering applications
Hosted Ginkgo’s first in-person investor day, which was also streamed live online, to highlight key business updates in Cell Engineering, Biosecurity and AI
Ginkgo’s Cell Engineering segment generated services revenue, which does not include downstream value share revenue, of $36 million, a 52% increase versus the third quarter of 2022
Ginkgo’s Biosecurity segment generated $18 million of revenue in the third quarter as Biosecurity revenue shifted away from COVID-19 testing programs in schools and communities towards a more recurring model focused on long-term biosecurity infrastructure
Concentric continues to expand its global bioradar network, with partnerships in 14 countries and 9 operational airport programs
Concentric is maturing its bioradar offering by expanding its partnership with CDC on air travel-based pathogen monitoring to more than 30 additional priority pathogens and launching new efforts in zoonotic disease monitoring, in the U.S. and internationally
Concentric is building a suite of next-generation biological intelligence capabilities, including AI-based epidemic forecasting





Third Quarter 2023 Financial Highlights
Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment
Third quarter 2023 Cell Engineering revenue of $37 million, up from $25 million in the comparable prior year period, an increase of 51%
Third quarter 2023 Biosecurity revenue of $18 million with gross profit margin of 62%
Third quarter 2023 Loss from operations of $(286) million (inclusive of stock-based compensation expense of $54 million and a non-cash impairment charge of $96 million relating to the exit of a Zymergen lease facility), compared to Loss from operations of $(655) million in the comparable prior year period (inclusive of stock-based compensation expense of $563 million). About half of the stock-based compensation expense relates to the continued GAAP accounting for the modification of restricted stock units issued prior to Ginkgo becoming a public company, as disclosed in our annual report on Form 10-K filed with the SEC on March 13, 2023, and which we expect will continue to ramp down significantly in the coming quarters
Third quarter 2023 Adjusted EBITDA of $(84) million, down from $(72) million in the comparable prior year period driven by both the higher run-rate of expenses in Cell Engineering and the as-expected decline in Biosecurity revenue
Cash and cash equivalents balance as of the end of the third quarter of over $1.0 billion puts Ginkgo in a strong financial position to pursue its strategic objectives

Full Year 2023 Outlook
While Ginkgo continues to see strong growth in its business development pipeline, based on third quarter results and pacing of new opportunities, Ginkgo revised its new Cell Programs target to a range of 80 - 85 new Cell Programs added to the platform in 2023. In addition, Ginkgo signed several technology licensing evaluation agreements in the third quarter, which do not involve Foundry service work and therefore, are not included in our Cell Program count, though they represent a new source of potential future revenue
Ginkgo is expecting Total revenue of $250 - $260 million in 2023
Ginkgo revised its expectations for Cell Engineering revenue to $145 - $150 million in 2023, inclusive of $4 million of downstream value share revenue recognized year-to-date
Based on solid third quarter results, Ginkgo revised its expectations for Biosecurity revenue to up to $110 million in 2023

Conference Call Details
Ginkgo will host a videoconference today, Wednesday, November 8, 2023, beginning at 5:30 p.m. ET. The presentation will include an overview of the third quarter financial performance, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:
+1 646 876 9923 (New York)
+1 301 715 8592 (Washington DC)
+1 312 626 6799 (Chicago)
+1 669 900 6833 (San Jose)
+1 253 215 8782 (Tacoma)
+1 346 248 7799 (Houston)
+1 408 638 0968 (San Jose)

Webinar ID: 969 1616 2296

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our web site at https://investors.ginkgobioworks.com/events/ for updated dial-in information.




About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) or LinkedIn.


Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our balance sheet and cash runway, acquisitions, current expectations, operations and anticipated results of operations, both business and financial, including opportunities for increased operational efficiency, potential customer success, including successful application of our offerings by our customers, the capabilities and potential operational and financial success of our partnerships and collaborations, and expected timing thereof, expectations with regard to revenue, the nature of such revenue and any related downstream value share associated with such revenue, funding that is contingent upon Ginkgo’s achievement of milestones, expenses, including our stock-based compensation expenses, our full year 2023 outlook, the future security and commercial applications of the BIOINT industry, the expansion and potential capabilities of our bioradar network and the national biodefense strategy, the achievement of milestones in our partnership with Google and the expected timing thereof, plans to develop and deploy AI tools for biology and biosecurity for both internal use and external release, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC"), and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.








Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.


Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
investors@ginkgobioworks.com

MEDIA CONTACT:
press@ginkgobioworks.com



Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except per share data, unaudited)
As of September 30, 2023As of December 31, 2022
Assets
Current assets:
Cash and cash equivalents

$ 1,049,244$ 1,315,792
Accounts receivable, net

61,89780,907
Accounts receivable - related parties

1,2461,558
Inventory, net

704,364
Prepaid expenses and other current assets

29,38947,458
Total current assets

1,141,8461,450,079
Property, plant and equipment, net201,595314,773
Operating lease right-of-use assets341,614400,762
Investments84,970112,188
Equity method investments1,1201,543
Intangible assets, net100,168111,041
Goodwill58,05760,210
Other non-current assets97,02288,725
Total assets

$ 2,026,392$ 2,539,321
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

$ 10,753$ 10,451
Deferred revenue

42,76247,817
Accrued expenses and other current liabilities

114,947114,694
Total current liabilities

168,462172,962
Non-current liabilities:
Deferred revenue, net of current portion

170,011174,767
Operating lease liabilities, non-current

403,662413,256
Warrant liabilities

12,25510,868
Other non-current liabilities

19,31931,191
Total liabilities

773,709803,044
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value
Common stock, $0.0001 par value198190
Additional paid-in capital6,334,2186,136,378
Accumulated deficit(5,078,834)(4,397,659)
Accumulated other comprehensive loss(2,899)(2,632)
Total stockholders’ equity1,252,6831,736,277
Total liabilities and stockholders’ equity$ 2,026,392$ 2,539,321










Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data, unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
20232022 (as adjusted*)20232022 (as adjusted*)
Cell Engineering revenue$ 37,176$ 24,679$ 116,555$ 90,409
Biosecurity revenue:
Product6,4955,19028,94923,024
Service11,75936,52971,196265,988
Total revenue55,43066,398216,700379,421
Costs and operating expenses:
Cost of Biosecurity product revenue9062,6607,48113,199
Cost of Biosecurity service revenue6,01721,99539,913160,799
Research and development (1)
156,662261,460463,583875,095
General and administrative (1)
82,028435,221295,8021,308,416
Impairment of lease assets96,21096,210
Total operating expenses341,823721,336902,9892,357,509
Loss from operations(286,393)(654,938)(686,289)(1,978,088)
Other (expense) income:
Interest income, net15,0206,38043,9148,821
Loss on equity method investments(22,711)(1,516)(53,764)
Loss on investments(36,324)(1,758)(44,815)(39,981)
Change in fair value of warrant liabilities1,891(12,445)(1,387)96,099
Gain on deconsolidation of subsidiaries15,98931,889
Other income (expense), net2,893(676)9,0451,473
Total other (expense) income, net(16,520)(15,221)5,24144,537
Loss before income taxes(302,913)(670,159)(681,048)(1,933,551)
Income tax (benefit) provision(22)(28)127(257)
Net loss(302,891)(670,131)(681,175)(1,933,294)
Loss attributable to non-controlling interest(3,833)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (302,891)$ (670,131)$ (681,175)$ (1,929,461)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted$ (0.16)$ (0.41)$ (0.35)$ (1.19)
Weighted average common shares outstanding, basic and diluted1,950,8141,630,9111,933,2021,619,790
Comprehensive loss:
Net loss$ (302,891)$ (670,131)$ (681,175)$ (1,933,294)
Other comprehensive loss:
Foreign currency translation adjustment(1,599)(2,414)(267)(6,195)
Total other comprehensive loss(1,599)(2,414)(267)(6,195)
Comprehensive loss$ (304,490)$ (672,545)$ (681,442)$ (1,939,489)
* As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”). See Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for a summary of the adjustments.
(1)R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense, inclusive of employer payroll taxes, was allocated as follows (in thousands):




Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)20232022 (as adjusted*)20232022 (as adjusted*)
Research and development$ 33,976$ 187,019$ 122,086$ 670,650
General and administrative19,671376,36669,2381,159,040
Total$ 53,647$ 563,385$ 191,324$ 1,829,690



Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
Nine Months Ended September 30,
20232022 (as adjusted*)
Cash flows from operating activities:
Net loss$ (681,175)$ (1,933,294)
Adjustments to reconcile net loss to net cash used in operating activities: 
Depreciation and amortization

57,67026,885
Stock-based compensation

187,047 1,822,472
Loss on investments and equity method investments

46,33193,745
Change in fair value of warrant liabilities

1,387(96,099)
Change in fair value of contingent consideration liability

10,217 58
Gain on deconsolidation of subsidiaries

(31,889)
Impairment of long-lived assets

121,404 
Non-cash customer consideration

(884)(18,139)
Non-cash lease expense

24,635 11,877
Non-cash in-process research and development

3,981 1,162
Other non-cash activity

3,9374,602
Changes in operating assets and liabilities:

 
Accounts receivable

21,16820,521
Prepaid expenses and other current assets

13,5575,230
Operating lease right-of-use assets

9,277
Other non-current assets

(2,733)144
Accounts payable, accrued expenses and other current liabilities

(4,822)(11,852)
Deferred revenue, current and non-current

(29,382)(35,365)
Operating lease liabilities, current and non-current

(18,310)(7,807)
Other non-current liabilities

(974)82
Net cash used in operating activities
(237,669)(147,667)
Cash flows from investing activities:
Purchase of convertible note (10,000)
Purchases of property and equipment(37,355)(26,626)
Proceeds from sale of equipment3,000 110
Purchase of investment in equity securities(3,691)
Deconsolidation of subsidiaries - cash (55,721)
Other336(1,206)
Net cash used in investing activities

(34,019)(97,134)



Cash flows from financing activities: 
Principal payments on finance leases(977) (912)
Contingent consideration payment(1,082)(521)
Other(525) (993)
Net cash used in financing activities

(2,584)(2,426)
Effect of foreign exchange rates on cash and cash equivalents(690) (191)
Net decrease in cash, cash equivalents and restricted cash
(274,962)(247,418)
Cash and cash equivalents, beginning of period1,315,7921,550,004
Restricted cash, beginning of period53,789 42,924
Cash, cash equivalents and restricted cash, beginning of period1,369,5811,592,928
Cash and cash equivalents, end of period1,049,2441,302,603
Restricted cash, end of period45,375 42,907
Cash, cash equivalents and restricted cash, end of period$ 1,094,619$ 1,345,510
* As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for a summary of the adjustments.




Ginkgo Bioworks Holdings, Inc.
Selected Non-GAAP Financial Measures
(in thousands, unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
20232022 (as adjusted*)20232022 (as adjusted*)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (302,891)$ (670,131)$ (681,175)$ (1,929,461)
Interest income, net(15,020)(6,380)(43,914)(8,821)
Income tax (benefit) provision(22)(28)127(257)
Depreciation and amortization21,0608,91757,67026,885
EBITDA(296,873)(667,622)(667,292)(1,911,654)
Stock-based compensation (1)
53,647563,385191,3241,829,690
Loss on equity method investments (2)
22,7111,51652,927
Loss on investments36,3241,75844,81539,981
Change in fair value of warrant liabilities(1,891)12,4451,387(96,099)
Gain on deconsolidation of subsidiaries(15,989)(31,889)
Merger and acquisition related expenses (3)
12,25312,01747,10820,184
Impairment of long-lived assets (4)
112,403121,404
Change in fair value of convertible notes317(561)121(229)
Adjusted EBITDA$ (83,820)$ (71,856)$ (259,617)$ (97,089)
* As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for a summary of the adjustments.
(1)For the three and nine months ended September 30, 2023, includes $1.1 million and $0.2 million, respectively, in employer payroll taxes. For the three and nine months ended September 30, 2022, includes $4.3 million and $7.2 million, respectively, in employer payroll taxes.
(2)Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests.
(3)Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, (iv) acquired intangible assets expensed as in-process research and development associated with asset acquisitions and (v) costs associated with the Zymergen bankruptcy.
(4)For the three months ended September 30, 2023, includes $16.2 million impairment loss on lab equipment and $96.2 million impairment loss on a right-of-use asset and the related leasehold improvements associated with an exited Zymergen leased facility. For the nine months ended September 30, 2023, includes $25.2 million impairment loss on lab equipment and $96.2 million impairment loss on a right-of-use asset and the related leasehold improvements associated with an exited Zymergen leased facility.







Ginkgo Bioworks Holdings, Inc.
Segment Information
(in thousands, unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023
2022 (as adjusted*)
2023
2022 (as adjusted*)
Revenue:
Cell Engineering
$ 37,176$ 24,679$ 116,555$ 90,409
Biosecurity
18,25441,719100,145289,012
Total revenue
55,43066,398216,700379,421
Segment cost of revenue:
Biosecurity
6,92324,65547,394173,998
Segment research and development expense:
Cell Engineering
90,88965,589275,494177,948
Biosecurity
3133871,4081,347
Total segment research and development expense
91,20265,976276,902179,295
Segment general and administrative expense:
Cell Engineering
42,61741,606155,216104,900
Biosecurity
12,20717,03942,86242,683
Total segment general and administrative expense
54,82458,645198,078147,583
Segment operating (loss) income:
Cell Engineering
(96,330)(82,516)(314,155)(192,439)
Biosecurity
(1,189)(362)8,48170,984
Total segment operating loss
(97,519)(82,878)(305,674)(121,455)
Operating expenses not allocated to segments:
Stock-based compensation (1)
53,647563,385191,3241,829,690
Depreciation and amortization
21,0608,91757,67026,885
Impairment of long-lived assets
112,403121,404
Change in fair value of contingent consideration liability1,764(242)10,21758
Loss from operations
$ (286,393)$ (654,938)$ (686,289)$ (1,978,088)
* As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for a summary of the adjustments.
(1)Includes $1.1 million and $0.2 million in employer payroll taxes for the three months ended September 30, 2023 and 2022, respectively, and $4.3 million and $7.2 million in employer payroll taxes for the nine months ended September 30, 2023 and 2022, respectively.



v3.23.3
Cover Page
Nov. 08, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 08, 2023
Entity Registrant Name GINKGO BIOWORKS HOLDINGS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40097
Entity Tax Identification Number 87-2652913
Entity Address, Address Line One 27 Drydock Avenue
Entity Address, Address Line Two 8th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code 877
Local Phone Number 422-5362
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001830214
Amendment Flag false
Class A common stock, par value $0.0001 per share  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol DNA
Security Exchange Name NYSE
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share  
Document Information [Line Items]  
Title of 12(b) Security Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol DNA.WS
Security Exchange Name NYSE

Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ginkgo Bioworks Charts.
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ginkgo Bioworks Charts.